Literature DB >> 9689586

Effects of levosimendan on myocardial contractility and Ca2+ transients in aequorin-loaded right-ventricular papillary muscles and indo-1-loaded single ventricular cardiomyocytes of the rabbit.

S Sato1, M A Talukder, H Sugawara, H Sawada, M Endoh.   

Abstract

Effects of levosimendan on myocardial contractility and Ca2+ transients were assessed in the ventricular myocardium of the rabbit. Levosimendan at and above 0.1 microM had a concentration-dependent positive inotropic effect (PIE) on isolated papillary muscles that had been loaded with aqeuorin. The maximum inotropic response to levosimendan at 3 microM was approximately 20% of the maximum response to isoproterenol (ISOmax), whereas the maximum increase in the amplitude of Ca2+ transients was approximately 11% of ISOmax. For a given PIE, levosimendan increased the amplitude of Ca2+ transients much less than an elevation of [Ca2+]o. Levosimendan did not prolong the relaxation time. Similar results were obtained in single ventricular cardiomyocytes that had been loaded with indo-1. In the presence of the muscarinic receptor agonist carbachol, both the PIE and the increase in the Ca2+ transient induced by levosimendan were markedly attenuated. During wash-out of both carbachol and levosimendan, the contractile force increased conspicuously with little change in the amplitude of Ca2+ transients, an indication that the increase in myofibrillar sensitivity to Ca2+ ions elicited by levosimendan was susceptible to carbachol. Levosimendan at and above 0.03 microM shifted the concentration-response curve for isoproterenol to the left. Levosimendan had a positive chronotropic effect at 0.01 microM and higher in the isolated right atrium of the rabbit. These findings indicate that, in addition to the increase by levosimendan of the sensitivity of contractile proteins to Ca2+ ions, the accumulation of cyclic AMP due to the phosphodiesterase-inhibitory action of levosimendan might contribute to the PIE of this drug.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9689586     DOI: 10.1006/jmcc.1998.0677

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  15 in total

1.  3D printed micro-scale force gauge arrays to improve human cardiac tissue maturation and enable high throughput drug testing.

Authors:  Xuanyi Ma; Sukriti Dewan; Justin Liu; Min Tang; Kathleen L Miller; Claire Yu; Natalie Lawrence; Andrew D McCulloch; Shaochen Chen
Journal:  Acta Biomater       Date:  2018-12-19       Impact factor: 8.947

Review 2.  Targeting the sarcomere to correct muscle function.

Authors:  Peter M Hwang; Brian D Sykes
Journal:  Nat Rev Drug Discov       Date:  2015-04-17       Impact factor: 84.694

3.  Levosimendan restores the positive force-frequency relation in heart failure.

Authors:  Satoshi Masutani; Heng-Jie Cheng; Hideo Tachibana; William C Little; Che-Ping Cheng
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-05-13       Impact factor: 4.733

Review 4.  Future pharmacologic agents for treatment of heart failure in children.

Authors:  Brady S Moffett; Anthony C Chang
Journal:  Pediatr Cardiol       Date:  2006-08-23       Impact factor: 1.655

5.  Levosimendan for Septic Myocardial Dysfunction: Not Yet Ready for Prime Time.

Authors:  Diana Pang; Rajesh K Aneja
Journal:  Crit Care Med       Date:  2015-11       Impact factor: 7.598

6.  Reversal of isoflurane-induced depression of myocardial contraction by nitroxyl via myofilament sensitization to Ca2+.

Authors:  Wengang Ding; Zhitao Li; Xiaoxu Shen; Jackie Martin; S Bruce King; Vidhya Sivakumaran; Nazareno Paolocci; Wei Dong Gao
Journal:  J Pharmacol Exp Ther       Date:  2011-08-24       Impact factor: 4.030

7.  Dual regulation of myofilament Ca2+ sensitivity by levosimendan in normal and acidotic conditions in aequorin-loaded canine ventricular myocardium.

Authors:  Reiko Takahashi; Masao Endoh
Journal:  Br J Pharmacol       Date:  2005-08       Impact factor: 8.739

8.  Levosimendan and its metabolite OR-1896 elicit KATP channel-dependent dilation in resistance arteries in vivo.

Authors:  Ildikó Gödény; Piero Pollesello; István Edes; Zoltán Papp; Zsolt Bagi
Journal:  Pharmacol Rep       Date:  2013       Impact factor: 3.024

9.  Inhibition of phosphodiesterase-3 by levosimendan is sufficient to account for its inotropic effect in failing human heart.

Authors:  O Orstavik; S H Ata; J Riise; C P Dahl; G Ø Andersen; F O Levy; T Skomedal; J-B Osnes; E Qvigstad
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

10.  Defining the binding site of levosimendan and its analogues in a regulatory cardiac troponin C-troponin I complex.

Authors:  Ian M Robertson; Olga K Baryshnikova; Monica X Li; Brian D Sykes
Journal:  Biochemistry       Date:  2008-06-21       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.